Life Sciences BPO Market to Flourish with an Impressive CAGR by 2027

AI and ML Provide Actionable Insights for Intelligent Drug Discovery

Gene therapies, intelligent drug discovery, telemedicine, and the likes are bringing about a change in the life sciences BPO market. Companies in the market for life sciences BPO are innovating through AI and machine learning (ML) for drug discovery. For instance, in June 2019, Navitas Life Sciences— a company that delivers platform-driven clinical solutions and services, announced to partner with ThoughtSphere— a cloud-based clinical data hub and analytics SaaS company, to use AI and ML in order to deliver unparalleled data collection.

The life sciences BPO market is estimated to grow at a favorable CAGR of ~8% during the forecast period. Companies in the market landscape are increasing their efficiency to develop analytical platforms that offer best-in-class clinical data oversight and actionable insights for faster decision making. Companies in the market for life sciences BPO are using the advantages of AI and ML to deliver improved data collection, while significantly reducing costs involved with mapping highly complex studies.

Request Sample Of Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1782

Proactive and Intelligent Functioning of Pharmaceutical Firms Improve Patient Outcomes

Pharmacovigilance (PV) is shaping the future of the life sciences BPO market. This explains why the revenue of contract research organizations is predicted for aggressive growth during the forecast period and the life sciences BPO market is expected to reach a value of ~US$ 420 Bn by the end of 2027. Pharmaceutical companies in market for life sciences BPO are increasing their R&D activities and clinical trials to ensure drug safety in a patient-centric and digital era where companies are introducing innovative mechanisms to avoid adverse events following a drug’s launch.

Pharmaceutical firms are increasing efforts to engage with patients who are willingly taking ownership of their health outcomes. The life sciences BPO market is witnessing a wave of transformation, as PV is evolving from a regulation-driven, transactional exercise to a more proactive and intelligent model. Such transformations are forming an integral part of the clinical and R&D lifecycle of pharma companies.

Request the Coronavirus Impact Analysis on this Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1782

Strategic Alliances with Startups Catalyze Growth of Life Sciences BPO Market

The life sciences BPO market is largely fragmented with 10 key players accounting for ~54% of the market share. This indicates that new entrants and startups are giving a tough competition to leading players. Hence, there is a growing need for strategic alliances between big companies and startups to address challenges in the market for life sciences BPO.

As suggested by the Everest Group-a Texas-based management consulting and research firm, as big companies join forces with new entrants, they can cohesively tackle challenges of stagnating growth and stringent regulations with next-gen technology tenets such cognitive computing to improve operational efficiency.

Blockchain and serialization techniques are addressing the issues of counterfeit drugs in the market for life sciences BPO. Several drivers such as data management and virtual trials are offering a big-picture view of clinical results and are speeding up go/no-go decisions. Growing awareness about investments in specialist therapies and personalized medicines are triggering market growth.

Buy _ Research Report Now – https://www.transparencymarketresearch.com/checkout.php?rep_id=1782&ltype=S

RPA Technology Addressing Patient-centricity and Leveraging Medical Drug Research

The robotic process automation (RPA) technology is sweeping the life sciences BPO market. Outsourcing repetitive tasks and manual processes using the RPA technology is anticipated to become increasingly mainstream in developing economies of Asia Pacific. Apart from Asia Pacific, this market in both North America and Europe is estimated to witness growth in terms of revenue during the forecast period. Thus, the RPA technology is expected to generate incremental opportunities for companies in the life sciences BPO market.

The life sciences industry is in its transformative stage where there is a growing need for effective medicines and personalized digital therapeutics that improve quality of life in patients. Hence, companies in the market for life sciences BPO are increasing their focus in the RPA technology and other software robots to provide cognitive automation in medical drug research. Intelligent RPA is helping companies to address patient-centricity and eliminating manual processes. Moreover, AI and ML are helping to optimize processes, streamline costs, and improve care outcomes.

More Trending Reports by Transparency Market Research – https://www.biospace.com/article/artificial-limbs-market-introduction-of-robotic-artificial-limbs-to-drive-market-to-new-heights/